The antihypertensive agent ACT ‐132577 alleviates cuproptosis and pressure‐overload‐induced vascular remodelling by modulation of the NEDD4‐LCTR1‐copper signaling
The FEBS Journal · 2026
DOI: 10.1111/febs.70341 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Rui Qiang Qi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital and Beijing Institute of Respiratory Medicine, Capital Medical Uni…. Hauptthemen laut MEDLINE: Vascular Remodeling, Copper, Antihypertensive Agents, Nedd4 Ubiquitin Protein Ligases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Health Commission of China, National Major Science and Technology Projects, National Natural Science Foundation of China.
Abstract (Originalsprache)
ACT‐132577 is a newly approved anti‐hypertensive agent in the treatment of hypertension and related cardiovascular diseases. However, its exact roles and underlying mechanisms beyond simple blood pressure regulation remain largely unclear. This study aims to elucidate the role of ACT‐132577 in CTR1–copper–cuproptosis signalling and vascular injury. Twelve‐week‐old spontaneously hypertensive rats (SHRs) and eight‐week‐old C57BL/6J mice undergoing abdominal aortic constriction (AAC) and primary vascular smooth muscle cells (VSMCs) were used to investigate the effects of ACT‐132577 on vascular remodelling. Administration of ACT‐132577 effectively reduced copper levels and Copper Transporter 1 (CTR1) protein expression in aortic tissues. These changes were linked to alleviation of cuproptosis, evidenced by increased levels of Ferredoxin1, lipoylated‐Dihydrolipoamide S‐Acetyltransferase (lipo‐DLAT) and lipo‐Dihydrolipoamide S‐Succinyltransferase (lipo‐DLST), as well as lower levels of DLAT oligomer and heat shock protein 70. Additionally, both ACT‐132577 and tetrathiomolybdate treatment strikingly mitigated vascular remodelling in SHRs, with decreases in medial thickness, vascular diameter and the cross‐sectional area of blood vessels. In vitro experiments corroborated these findings, revealing that ACT‐132577 suppressed platelet‐derived growth factor subunit beta‐induced VSMC phenotypic transition, which was evidenced by reduced cellular migration, maintained cell contractility, upregulated contractile markers (SM22a, Acta2, Myh11) and downregulated secretory markers (MMP2, MMP9, OPN). Mechanistically, ACT‐132577 upregulated E3 ubiquitin‐protein ligase NEDD4‐like (NEDD4L), thus promoting K48 ubiquitination of CTR1. More importantly, knocking down NEDD4L significantly abolished the effects of ACT‐132577 on cuproptosis and VSMC phenotypic transition. In conclusion, ACT‐132577 plays a crucial role in cuproptosis and aortic remodelling by modulation of the NEDD4L–CTR1–copper signaling, providing a novel perspective on its therapeutic potential in mitigating pressure overload‐induced vascular remodelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital and Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, China.
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Jiu-Chang Zhong
Förderung
- National Health Commission of China, National Major Science and Technology Projects
- National Natural Science Foundation of China
Zitieren
APA
Qi, R. Q., Chen, Y. F., Yang, X. Y., Dong, Z. J., Zhao, L., Li, W. M., Cheng, J., Wang, Q., Li, J., & Zhong, J. C. (2026). The antihypertensive agent ACT ‐132577 alleviates cuproptosis and pressure‐overload‐induced vascular remodelling by modulation of the NEDD4‐LCTR1‐copper signaling. The FEBS Journal. https://doi.org/10.1111/febs.70341
Vancouver
Qi RQ, Chen YF, Yang XY, Dong ZJ, Zhao L, Li WM, et al. The antihypertensive agent ACT ‐132577 alleviates cuproptosis and pressure‐overload‐induced vascular remodelling by modulation of the NEDD4‐LCTR1‐copper signaling. The FEBS Journal. 2026. doi:10.1111/febs.70341
BibTeX
@article{Qi2026,
author = {Qi, Rui Qiang and Chen, Yu Fei and Yang, Xiao-Yan and Dong, Zhao Jie and Zhao, Lin and Li, Wei-Ming and Cheng, Jing and Wang, Qi and Li, Jing and Zhong, Jiu-Chang},
title = {The antihypertensive agent ACT ‐132577 alleviates cuproptosis and pressure‐overload‐induced vascular remodelling by modulation of the NEDD4‐LCTR1‐copper signaling},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70341}
}
EUVIMED